[{"orgOrder":0,"company":"Immatics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$50.0 million","newsHeadline":"GSK pays $50M for 2 solid tumor cell therapies from Immatics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Allogeneic T-cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immatics","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Immatics \/ GlaxoSmithKline","highestDevelopmentStatusID":"2","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Arya Sciences Acquisition Corp","pharmaFlowCategory":"D","amount":"$252.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces Business Combination with Arya Sciences Acquisition Corp\r\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"T cell immunotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Immatics \/ Arya Sciences Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Provides Update on IMA204 ACTengine\u00ae Cell Therapy Program Targeting the Tumor Microenvironment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA204","moa":"COL6A3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4\/8","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Phase I Data from ACTolog\u00ae Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine\u00ae Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"IMA201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"IMA402","moa":"T cell engaging receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$920.0 million","upfrontCash":"$150.0 million","newsHeadline":"Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics\u2019 TCR Bispecific Program IMA401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"IMA401","moa":"MAGEA4\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0.92000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.92000000000000004,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA401","moa":"MAGEA4\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo\u00ae (nivolumab) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"TCR-T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Editas Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Gamma-delta T Cell Adoptive Cell Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Immatics","highestDevelopmentStatusID":"2","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine\u00ae TCR-T Candidate IMA203CD8 Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"CD8 alpha beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces $110 Million Underwritten Offering of Ordinary Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"IMA203","moa":"TCR-T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data Update on ACTengine\u00ae IMA203 TCR-T Monotherapy Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"TCR-T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,460.0 million","upfrontCash":"$60.0 million","newsHeadline":"Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":1.46,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.46,"dosageForm":"","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$505.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"TCR-T-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine\u00ae IMA203 TCR-T Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Initiates Phase 1\/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IMA402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$1,820.0 million","upfrontCash":"$120.0 million","newsHeadline":"Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":1.8200000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.8200000000000001,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine\u00ae IMA203 TCR-T Monotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data from ACTengine\u00ae IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces Pricing of $175 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."}]
Find Clinical Drug Pipeline Developments & Deals by Immatics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
